Veeva Systems (VEEV) Could Be 42% Undervalued After Q1 Beat And Higher Guidance
Veeva Systems (VEEV) has moved back into focus after fiscal Q1 results came in ahead of its own guidance, leading management to raise full-year revenue and adjusted earnings forecasts, supported by growing AI-driven products.
See our latest analysis for Veeva Systems.
The Q1 beat and higher guidance have helped Veeva Systems regain some momentum, with a 30 day share price return of 8.68% and a 90 day share price return of 16.07%. However, the 1 year total shareholder return is down 35.87% and the 5 year total shareholder return is down 44.02%, so recent optimism is building from a weak longer term base.
If you are looking for other healthcare focused AI opportunities alongside Veeva Systems, it could be worth scanning the market using the 40 healthcare AI stocks
After the post results bounce, Veeva Systems still trades at a sizeable discount to both analyst targets and intrinsic estimates, so is the market being overly cautious, or are investors right to treat that gap carefully?
Most Popular Narrative: 41.8% Undervalued
At a last close of $186.24 versus a narrative fair value of $320, Veeva Systems is framed as meaningfully undervalued, with that gap anchored in a detailed cash flow story.
The recent financial results show that the core business remains healthy. Falcon creates a credible opportunity to add AI-driven monetization across an existing life-sciences customer base. And the company’s balance sheet and profitability give it room to invest through market cycles.
Curious what sits behind that $320 figure and 41.8% discount call according to John_Eric? The narrative leans on durable margins, steady revenue expansion, and a valuation model that stretches cash flows many years out while applying a clear return hurdle. The tension between those assumptions and today’s share price is where the story gets interesting.
Result: Fair Value of $320 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Veeva Systems still faces real pressure points, including potential disruption from large pharmaceutical mergers and the risk that Falcon monetization or adoption falls short of investor expectations.
Find out about the key risks to this Veeva Systems narrative.
Next Steps
Does the mix of caution and optimism around Veeva Systems match your own read of the story, or does it feel off? Act quickly, review the data, and weigh these 3 key rewards
Looking for more investment ideas beyond Veeva Systems?
Do not stop at Veeva Systems alone. Use the Simply Wall Street Screener to compare fresh opportunities and keep your portfolio ideas flowing.
- Target potential bargains that line up with solid fundamentals by scanning the market using the 49 high quality undervalued stocks.
- Strengthen the quality of your holdings by filtering for companies with resilient finances through the solid balance sheet and fundamentals stocks screener (49 results).
- Spot opportunities others might overlook by running the screener containing 19 high quality undiscovered gems before the crowd catches on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com